Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
amxetine
- Development stage
- Unknown
- Lead developer
- Beijing Institute of Pharmacology and Toxicology
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Amxetine (amxetine hydrochloride) is a novel small molecule antidepressant developed by the Institute of Toxicology and Pharmacology at the Academy of Military Medical Sciences (AMMS) in China. It is designed as a triple reuptake inhibitor (SNDRI), a class of drugs that simultaneously inhibits the reuptake of serotonin, norepinephrine, and dopamine from the synaptic cleft. This multi-target mechanism is intended to provide broader therapeutic efficacy and potentially a faster onset of action compared to traditional selective serotonin reuptake inhibitors (SSRIs) or serotonin-norepinephrine reuptake inhibitors (SNRIs). Amxetine is formulated as enteric-coated tablets to optimize its pharmacokinetic profile and gastrointestinal tolerability. It has been evaluated in Phase 1 and Phase 2 clinical trials in China for the treatment of major depressive disorder.
- Other names
- amxetine hydrochlorideamxetine hydrochloride enteric-coated tablets
02
Targets
DAT (Dopamine plasma membrane transport protein)SERT (Sodium-dependent serotonin transporter)NET (Norepinephrine Transporter)
Beyond the preview
Go deeper on amxetine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on amxetine.